Analyst Consensus ?
ConsensusHold33 ratings
Bullish1648.5%
Neutral1648.5%
Bearish13.0%
Becton, Dickinson and Company · BDX · FY2026 Q4 · Calendar Q4 2026
BD FY2026: Broad Growth, With FY2027 Margin and Alaris Risks
BD entered FY2027 with broad momentum across Advanced Patient Monitoring, PureWick, biologic drug delivery and pharmacy automation. Management's outlook is measured: low-single-digit revenue growth and flat operating margins, with Alaris pressure weighing on the year.
Why did BDX rise 2.1% after beating EPS estimates in FY2026 Q4?
Research this report with FN2. Free to start; review your question before sending.
Reported Before market openNYSEHealthcare
$58.17B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$4.15
Consensus $4.07
EPS surprise
+2.0%
Reported versus consensus
Reported revenue
$5.27B
Consensus $5.11B
Revenue surprise
+3.1%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+2.1%
Event window
SPY move
-4.4%
Same window
Abnormal move
+6.5%
Stock minus SPY
Volume
2.3×
Versus trailing sessions
Subsequent drift
0.0%
Up to 20 sessions
BDXSPY benchmark
Ask FN2 about BDX FY2026 Q4
Choose a question to continue your research
Why did BDX rise 2.1% after beating EPS estimates in FY2026 Q4?What changed in BDX's guidance and outlook in FY2026 Q4?Give me the bull and bear case for BDX after FY2026 Q4 earnings.
Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Transcript intelligence
What changed
Compared with Q3, the year-end update reports stronger Q4 growth and completion of the life-sciences spin-off, leaving BD focused on medtech. Management shifted attention to FY2027, where it expects low-single-digit revenue growth and flat operating margins, while identifying Alaris as a material headwind.
Guidance delta
FY2027 guidance calls for low-single-digit revenue growth, flat operating margins and adjusted EPS of $13.10-$13.30. Management maintained this outlook; Alaris is expected to pressure revenue and margins during the year.
Key takeaways
- Q4 revenue grew 5.6% year over year to $5.3 billion, and adjusted EPS increased 27.3% to $4.15.
- Full-year revenue was $19.5 billion, up 3.9%; adjusted EPS was $12.70, up 6.7%.
- Growth was led by Advanced Patient Monitoring, PureWick, biologic drug delivery and pharmacy automation.
- The life-sciences spin-off is complete; BD describes itself as a focused medtech company.
Management priorities
- Expand product platforms through launches including Liverty, Phasix and HemoSphere Alta.
- Deploy Cognite and Incada AI across manufacturing and commercial functions.
- Expand U.S. manufacturing under the government partnership and pursue focused tuck-in M&A.
- Improve free-cash-flow conversion and sustain disciplined capital allocation.
Follow BDX with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$212.73Current
$159Low
$200.91Average
$242High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 6, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| B of A Securities | Neutral | Neutral | Maintain | Aug 31, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Aug 13, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Aug 7, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Aug 7, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 7, 2026 |
| TD Cowen | Hold | Hold | Maintain | Aug 5, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 6, 2026 |
| Barclays | Overweight | Overweight | Maintain | May 11, 2026 |
| Argus Research | Buy | Buy | Maintain | Mar 23, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Feb 10, 2026 |
| Jefferies | Buy | Buy | Maintain | Feb 10, 2026 |
| Stifel | Buy | Buy | Maintain | Jan 7, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Dec 2, 2025 |
| William Blair | Market Perform | Outperform | Downgrade | May 1, 2025 |
| Raymond James | Outperform | Outperform | Maintain | Aug 2, 2024 |
| Keybanc | Overweight | Sector Weight | Upgrade | Apr 12, 2023 |
| Goldman Sachs | Buy | Buy | Maintain | Nov 23, 2022 |
| SVB Leerink | Market Perform | Market Perform | Maintain | Feb 4, 2022 |
| UBS | Neutral | Neutral | Maintain | Aug 10, 2020 |
| CFRA | Hold | Hold | Maintain | May 8, 2020 |
| Cowen & Co. | Market Perform | Outperform | Downgrade | Feb 7, 2020 |
| Stifel Nicolaus | Buy | Buy | Maintain | Dec 16, 2019 |
| BMO Capital | Market Perform | Market Perform | Maintain | May 10, 2019 |
| Deutsche Bank | Buy | Buy | Maintain | Dec 7, 2018 |
| Bank of America | Neutral | Neutral | Maintain | Nov 5, 2014 |
| Canaccord Genuity | Hold | Hold | Maintain | Oct 7, 2014 |
| Argus | Buy | Buy | Maintain | Oct 7, 2014 |
| PiperJaffray | Overweight | Neutral | Upgrade | Sep 18, 2013 |
| ISI Group | Buy | Buy | Maintain | Jun 25, 2013 |
| Macquarie | Outperform | Neutral | Upgrade | May 10, 2013 |
| Mizuho | Neutral | Buy | Downgrade | Jan 22, 2013 |
| Leerink Swann | Market Perform | Outperform | Downgrade | Aug 3, 2012 |
| CLSA | Underperform | Outperform | Downgrade | Aug 3, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $212.73. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Jefferies | Matthew Taylor | $242 | $213.55 | +13.8% | Nov 5, 2026 |
| Barclays | Christopher Pasquale | $165 | $179.62 | -22.4% | Oct 7, 2026 |
| RBC Capital | Analyst unavailable | $190 | $184.04 | -10.7% | Aug 13, 2026 |
| Stifel Nicolaus | Analyst unavailable | $195 | $176.07 | -8.3% | Aug 7, 2026 |
| RBC Capital | Shagun Singh | $180 | $176.25 | -15.4% | Aug 7, 2026 |
| Jefferies | Analyst unavailable | $210 | $176.91 | -1.3% | Aug 6, 2026 |
| UBS | Analyst unavailable | $190 | $158.92 | -10.7% | Jul 28, 2026 |
| Evercore ISI | Analyst unavailable | $180 | $154.6 | -15.4% | Jul 6, 2026 |
| Barclays | Analyst unavailable | $204 | $149.43 | -4.1% | May 11, 2026 |
| Piper Sandler | Jason Bednar | $159 | $154.82 | -25.3% | Apr 17, 2026 |
| RBC Capital | Analyst unavailable | $175 | $155.43 | -17.7% | Apr 14, 2026 |
| Goldman Sachs | David Roman | $167 | $154.42 | -21.5% | Apr 10, 2026 |
| RBC Capital | Shagun Singh | $172 | $170.14 | -19.1% | Feb 10, 2026 |
| Barclays | Matt Miksic | $202 | $207.39 | -5.0% | Feb 10, 2026 |
| Piper Sandler | Analyst unavailable | $170 | $207.39 | -20.1% | Feb 10, 2026 |
| Piper Sandler | Jason Bednar | $161.16 | $159.91 | -24.2% | Jan 28, 2026 |
| Stifel Nicolaus | Analyst unavailable | $169.03 | $161.45 | -20.5% | Jan 7, 2026 |
| RBC Capital | Analyst unavailable | $165.09 | $154.39 | -22.4% | Dec 17, 2025 |
| Morgan Stanley | Patrick Wood | $165.09 | $150.8 | -22.4% | Dec 2, 2025 |
| Piper Sandler | Jason Bednar | $204.4 | $159.06 | -3.9% | Apr 23, 2025 |
| Evercore ISI | Vijay Kumar | $227.99 | $189.54 | +7.2% | Oct 1, 2024 |
| Citigroup | Joanna Wuensch | $216.19 | $190.2 | +1.6% | Oct 1, 2024 |
| Raymond James | Jayson Bedford | $212.26 | $187.96 | -0.2% | Aug 2, 2024 |
| Wells Fargo | Larry Biegelsen | $220.13 | $185.54 | +3.5% | Aug 2, 2024 |
| Evercore ISI | Becton Dickinson | $224.06 | $180.24 | +5.3% | Jul 2, 2024 |
| Goldman Sachs | David Roman | $215.41 | $176.94 | +1.3% | May 30, 2024 |
| Barclays | Matt Miksic | $245.28 | $184.5 | +15.3% | May 6, 2024 |
| Argus Research | David Toung | $235.85 | $190.83 | +10.9% | Apr 8, 2024 |
| Morgan Stanley | Analyst unavailable | $227.99 | $202.92 | +7.2% | Jan 6, 2023 |
| Citigroup | Analyst unavailable | $196.54 | $194.65 | -7.6% | Dec 12, 2022 |
| Goldman Sachs | Analyst unavailable | $213.84 | $185.9 | +0.5% | Nov 23, 2022 |
| Goldman Sachs | Analyst unavailable | $250.79 | $210.01 | +17.9% | Aug 16, 2022 |
| Stifel Nicolaus | Analyst unavailable | $220.13 | $187.4 | +3.5% | Jul 18, 2022 |
| Morgan Stanley | Analyst unavailable | $213.84 | $187.61 | +0.5% | Jul 15, 2022 |
| Citigroup | Analyst unavailable | $184.75 | $193.13 | -13.2% | Jul 11, 2022 |
| Wells Fargo | Larry Biegelsen | $231.92 | $197.26 | +9.0% | Jun 25, 2022 |
| Morgan Stanley | Analyst unavailable | $221.7 | $197.95 | +4.2% | May 6, 2022 |
| Piper Sandler | Analyst unavailable | $200.47 | $204.12 | -5.8% | May 6, 2022 |
| Bank of America Securities | Travis Steed | $227.99 | $209.27 | +7.2% | Mar 3, 2022 |
| Piper Sandler | Jason Bednar | $208.33 | $206.71 | -2.1% | Feb 3, 2022 |
Track every rating change on BDX the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationOperating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems.…
Historical context
All BDX earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| MRNA Moderna, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +7.3% | Moderna raises 2026 outlook as vaccines and oncology advance |
| MTD Mettler-Toledo International Inc. | FY2026 Q3 · Calendar Q4 2026 | +3.6% | +4.8% | Mettler-Toledo raises growth outlook after Q3 strength led by China |
| ELAN Elanco Animal Health Incorporated | FY2026 Q3 · Calendar Q4 2026 | — | +6.2% | Elanco lifts 2026 outlook as innovation products drive Q3 growth |
| GMAB Genmab A/S | FY2026 Q3 · Calendar Q4 2026 | +55.6% | -4.3% | Genmab pairs nine-month growth with a heavier launch agenda |
| NTRA Natera, Inc. | FY2026 Q3 · Calendar Q4 2026 | -49.3% | -15.2% | Natera raises 2026 revenue outlook as Signatera drives Q3 growth |
| STE STERIS plc | FY2027 Q2 · Calendar Q4 2026 | +9.7% | +2.5% | STERIS raises FY2027 EPS outlook after 9% revenue growth |
Latest beats and misses
Who reports nextBeat on EPS
- FNFFY2026 Q3 · November 5, 20260.0% EPS+6.6% move
- MTDFY2026 Q3 · November 5, 2026+3.6% EPS+4.8% move
- IAGFY2026 Q3 · November 5, 2026+16.7% EPS+4.6% move
- GMABFY2026 Q3 · November 5, 2026+55.6% EPS-4.3% move
- STEFY2027 Q2 · November 4, 2026+9.7% EPS+2.5% move
- IRMFY2026 Q3 · November 5, 2026+4.6% EPS-11.1% move
Missed on EPS
- VMRKFY2026 Q3 · November 4, 2026-425.6% EPS+2.4% move
- NTRAFY2026 Q3 · November 5, 2026-49.3% EPS-15.2% move
- TIGOFY2026 Q3 · November 5, 2026-40.8% EPS+2.6% move
- UHALFY2027 Q2 · November 4, 2026-15.4% EPS-3.2% move
- LAMRFY2026 Q3 · November 5, 2026-3.6% EPS-0.8% move
- CMIFY2026 Q3 · November 5, 2026-6.0% EPS-4.9% move
Get the BDX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-05T18:15:13.154321+00:00
- FN2 earnings calendar · 2026-11-06T01:23:16.275024+00:00
- Polygon adjusted daily market bars · 2026-11-06T10:40:45.796981+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-06T10:40:45.794350+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-06. For educational purposes only; not investment advice.